A phase II study of trifluridine/tipiracil and ramucirumab in patients with unresectable advanced or recurrent gastric cancer

被引：1
|
作者：
Ando, T. [1 ]
Kawazoe, A. [2 ]
Hosaka, H. [3 ]
Fujita, J. [4 ]
Koeda, K. [5 ]
Nishikawa, K. [6 ]
Amagai, K. [7 ]
Fujitani, K. [8 ]
Ogata, K. [9 ]
Yamamoto, Y. [10 ]
Shitara, K. [11 ]
机构：
[1] Toyama Univ Hosp, Dept Internal Med 3, Toyama, Japan
[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[3] Gunma Prefectural Canc Ctr, Div Gastroenterol, Ota, Japan
[4] Sakai City Med Ctr, Dept Surg, Sakai, Osaka, Japan
[5] Iwate Med Univ Hosp, Dept Surg, Shiwa, Japan
[6] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan
[7] Ibaraki Cent Hosp, Dept Gastroenterol, Kasama, Ibaraki, Japan
[8] Osaka Gen Med Ctr, Dept Surg Gastroenterol, Osaka, Japan
[9] Taiho Pharmeceut Co Ltd, Dept Med Affairs, Tokyo, Japan
[10] Taiho Pharmeceut Co Ltd, Dept Clin Dev, Tokyo, Japan
[11] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120MO
引用
收藏
页码：S1290 / S1290
页数：1
相关论文
共 50 条
  • [1] Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study
    Narita, Yukiya
    Ogata, Takatsugu
    Ishizuka, Yasunobu
    Sakakida, Tomoki
    Wakabayashi, Munehiro
    Kodama, Hiroyuki
    Honda, Kazunori
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [2] Trifluridine/tipiracil plus ramucirumab in gastric cancer
    Zhu, Mojun
    Sonbol, Mohamad Bassam
    Yoon, Harry H.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (03): : 154 - 155
  • [3] Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience
    Mashiro Okunaka
    Akihito Kawazoe
    Hitomi Nakamura
    Daisuke Kotani
    Saori Mishima
    Yasutoshi Kuboki
    Yoshiaki Nakamura
    Kohei Shitara
    Gastric Cancer, 2023, 26 : 1030 - 1039
  • [4] Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience
    Okunaka, Mashiro
    Kawazoe, Akihito
    Nakamura, Hitomi
    Kotani, Daisuke
    Mishima, Saori
    Kuboki, Yasutoshi
    Nakamura, Yoshiaki
    Shitara, Kohei
    GASTRIC CANCER, 2023, 26 (06) : 1030 - 1039
  • [5] Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer
    Nakanishi, Koki
    Tanaka, Chie
    Kanda, Mitsuro
    Miyata, Kazushi
    Machida, Nozomu
    Sakai, Mitsuru
    Kobayashi, Daisuke
    Teramoto, Hitoshi
    Ishiyama, Akiharu
    Sato, Bin
    Oshima, Takashi
    Kajikawa, Masaki
    Matsushita, Hidenobu
    Ishigure, Kiyoshi
    Yamashita, Katsuya
    Fujitake, Shinichi
    Sueoka, Satoshi
    Asada, Takahiro
    Shimizu, Dai
    Sugita, Shizuki
    Kuwatsuka, Yachiyo
    Maeda, Osamu
    Furune, Satoshi
    Murotani, Kenta
    Ando, Yuichi
    Ebata, Tomoki
    Kodera, Yasuhiro
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (01): : 43 - 51
  • [6] Randomized phase II trial of trifluridine/tipiracil plus ramucirumab versus trifluridine/tipiracil for pre-treated patients with advanced gastric or gastroesophageal junction adenocarcinoma (RETRIEVE study, WJOG15822G)
    Takahashi, N.
    Hara, H.
    Nagashima, K.
    Hirata, K.
    Masuishi, T.
    Matsumoto, T.
    Kawakami, H.
    Yamazaki, K.
    Hironaka, S.
    Boku, N.
    Muro, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S198 - S198
  • [7] Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
    Naoki Takahashi
    Hiroki Hara
    Kengo Nagashima
    Kenro Hirata
    Toshiki Masuishi
    Toshihiko Matsumoto
    Hisato Kawakami
    Kentaro Yamazaki
    Shuichi Hironaka
    Narikazu Boku
    Kei Muro
    BMC Cancer, 23 (1)
  • [8] Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
    Takahashi, Naoki
    Hara, Hiroki
    Nagashima, Kengo
    Hirata, Kenro
    Masuishi, Toshiki
    Matsumoto, Toshihiko
    Kawakami, Hisato
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Boku, Narikazu
    Muro, Kei
    BMC CANCER, 2023, 23 (01)
  • [9] An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer
    Takuro Mizukami
    Keiko Minashi
    Hiroki Hara
    Tomohiro Nishina
    Yusuke Amanuma
    Naoki Takahashi
    Akio Nakasya
    Masaki Takahashi
    Takako Eguchi Nakajima
    Investigational New Drugs, 2022, 40 : 614 - 621
  • [10] An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer
    Mizukami, Takuro
    Minashi, Keiko
    Hara, Hiroki
    Nishina, Tomohiro
    Amanuma, Yusuke
    Takahashi, Naoki
    Nakasya, Akio
    Takahashi, Masaki
    Nakajima, Takako Eguchi
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (03) : 614 - 621
12345